Home > Boards > Free Zone > User's Groups > Toxic Filings (TOXIC)

ASTM $16M left in shelf, down 12%+

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
sludgehound Member Profile
 
Followed By 65
Posts 13,841
Boards Moderated 0
Alias Born 01/05/03
160x600 placeholder
sludgehound   Monday, 12/02/13 10:09:01 AM
Re: None
Post # of 8407 
ASTM $16M left in shelf, down 12%+

Trading lower 3.80 -.55

Form 8-K for AASTROM BIOSCIENCES INC

29-Nov-2013

Entry into a Material Definitive Agreement, Financial Statements and Exhi

Item 1.01. Entry into a Material Definitive Agreement
On June 16, 2011, Aastrom Biosciences, Inc., a Michigan corporation (the "Company") entered into an At Market Issuance Sales Agreement (the "Sales Agreement") with MLV & Co. LLC ("MLV") pursuant to which the Company has previously sold an aggregate of $4.4 million of its common stock through MLV, acting as agent. On November 29, 2013, the Company and MLV entered into an Amendment No. 1 to the Sales Agreement in order to reference a new registration statement and prospectus under which sales can be made (because of the expiration of the prior registration statement). The amendment left unchanged the aggregate offering price which may be offered under the Sales Agreement and approximately $15.9 million remains available for issuance.

The description of Amendment No. 1 to the Sales Agreement set forth above is qualified in its entirety by reference to the Amendment No. 1 to At Market Issuance Sales Agreement filed as an exhibit to this Current Report on Form 8-K and incorporated herein by this reference. The original At Market Issuance Sales Agreement was previously filed by the Company as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on June 16, 2011.

The shares will be issued pursuant to the Company's shelf registration statement (the "Registration Statement") on Form S-3 (File No. 333-174945) filed on June 16, 2011 with the SEC. In connection with the offering contemplated by the Sales Agreement, the Company has filed a prospectus supplement, dated November 29, 2013 to the prospectus, dated July 18, 2011 that is part of the Registration Statement.





Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.




Exhibit
Number Description
1.1 Amendment No.1 to At Market Issuance Sales Agreement between Aastrom
Biosciences, Inc. and MLV & Co. LLC dated November 29, 2013.
5.1 Opinion of Dykema Gossett PLLC
23.1 Consent of Dykema Gossett PLLC (included as part of Exhibit 5.1)



It is hard to imagine a more stupid or more dangerous way of making decisions than by putting those decisions in the hands of people who pay no price for being wrong.

~ Thomas Sowell
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist